Welcome to our dedicated page for Miromatrix Medical news (Ticker: MIRO), a resource for investors and traders seeking the latest updates and insights on Miromatrix Medical stock.
Miromatrix Medical Inc. (MIRO) is revolutionizing organ transplantation through its proprietary bioengineering technology. This dedicated news hub provides investors and medical professionals with essential updates on the company's progress in addressing the global organ shortage crisis.
Access timely updates including quarterly financial results, clinical trial milestones, leadership developments, and strategic partnerships. Our curated collection features verified information about MIRO's perfusion platform advancements and industry recognition, such as their recent American Transplant Congress honors.
Key content categories include regulatory updates, research publications, executive team announcements, and manufacturing scale-up progress. Bookmark this page to stay informed about MIRO's pioneering work in creating transplant-ready human organs through their decellularization technology.
Miromatrix Medical Inc. is set to present its pioneering bioengineering technology at the Bioregate European Regenerative Medicine Forum from September 21-23, 2022, in Louvain-la-Neuve, Belgium. CEO Jeff Ross will deliver the keynote speech on September 21 at 3:05 pm CEST. The event focuses on the themes of repair, replacement, regeneration, and reprogramming in regenerative medicine, organized by several prestigious universities and organizations. Miromatrix aims to address the shortage of transplantable human organs, focusing on liver and kidney bioengineering.
Miromatrix Medical (NASDAQ: MIRO) received a new patent for its perfusion decellularization and recellularization technology, titled U.S. Patent Number 11,414,644. This patent enhances their existing portfolio, covering methods for revascularizing decellularized organs such as the liver, lung, kidney, and heart. CEO Jeff Ross highlights the significance of this technology in addressing the global organ transplantation crisis. The company boasts 119 issued and 34 pending patents globally, focusing on bioengineering transplantable organs, particularly livers and kidneys.
Miromatrix Medical Inc. (NASDAQ: MIRO) announced its participation in the Gilmartin Emerging Growth Company Showcase on August 31, 2022, at 9:30 am ET. The event will feature a presentation from Miromatrix management, which can be accessed via a live and archived webcast. Miromatrix is focused on bioengineering fully transplantable human organs, primarily human livers and kidneys, using its proprietary perfusion technology platform to address the organ shortage crisis.
Miromatrix Medical Inc. (NASDAQ: MIRO) reported its Q2 2022 financial results on August 15, 2022, highlighting ongoing advancements in bioengineering transplantable organs. With $38.6 million in cash, the company believes its resources can sustain operations through 2023. Significant progress includes successfully bioengineering kidneys and preparing to file an IND for MiroliverELAP™ by year-end. However, the company recorded an operating loss of $8.2 million, increasing from $3.6 million in Q2 2021, largely due to raised R&D and administrative costs.
Miromatrix Medical Inc. (NASDAQ: MIRO) has appointed Dr. Jack Lake as its new Medical Director. Dr. Lake is a Professor and Chief of Hepatology at the University of Minnesota, bringing extensive experience in liver and organ transplantation. He aims to enhance Miromatrix's mission of eliminating transplant waiting lists through bioengineering organs. With a focus on human livers and kidneys, Miromatrix is pioneering technology to address organ shortages. The company remains committed to advancing its innovative perfusion technology platform for organ bioengineering.
Miromatrix Medical Inc. (NASDAQ: MIRO) will announce its second quarter 2022 financial results on August 15, 2022, after market close. A conference call is scheduled for 3:30 PM CT to discuss these results. Miromatrix focuses on bioengineering fully transplantable human organs, specifically targeting human livers and kidneys. The company utilizes a proprietary perfusion technology platform to scale organ production and address the organ shortage crisis. For more details, visit their investor relations website.
Miromatrix Medical Inc. (NASDAQ: MIRO) recently commended the FDA for its two-day public advisory committee meeting focused on organ transplantation, especially xenotransplantation. The FDA acknowledged the critical shortage of human organs for transplant and the need for innovative solutions. Miromatrix shared its proprietary decellularization and recellularization technology, which aims to create transplantable organs without classifying as xenotransplantation. This technology may potentially reduce organ rejection risks by replacing pig cells with human cells, addressing historical challenges in organ transplantation.
Miromatrix Medical Inc. (NASDAQ: MIRO) announced its participation in the 2022 American Transplant Congress from June 4 to June 8, 2022. The company is focused on bioengineering fully transplantable organs, specifically human livers and kidneys, using a proprietary perfusion technology. This innovation aims to address the critical shortage of available human organs and enhance patient outcomes. Miromatrix’s unique approach positions it at the forefront of life sciences, potentially transforming organ transplantation.
Miromatrix Medical Inc. (NASDAQ: MIRO) announced participation in the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022. This event will not feature a webcast. Miromatrix is focused on bioengineering fully transplantable organs, using its proprietary perfusion technology to address organ shortages, specifically targeting human livers and kidneys. The company aims to save and improve patients' lives through its innovative approach to organ development.
Miromatrix Medical Inc. (NASDAQ: MIRO) announced its participation in the H.C. Wainwright Annual Global Investment Conference scheduled for May 24, 2022. The company specializes in bioengineering transplantable organs to address organ shortages. Interested parties can access the presentation via webcast starting at 7 am ET on the conference date. Miromatrix focuses on developing human livers and kidneys using proprietary technology to improve patient lives.
